Panacea Biotec supplies first shipment of Sputnik V second component produced in India

Panacea Biotec and the Russian Direct Investment Fund (RDIF) said that the former has supplied the first shipment of the second component of the Russian Sputnik V Covid vaccine manufactured by it for sale in India.

According to the Indian vaccine and pharma manufacturer, the first shipment which was made comprised a million doses of the second component (human adenovirus serotype 5).

Panacea Biotec had manufactured them at its vaccine manufacturing facility in Himachal Pradesh having secured the required clearance from Central Drug Laboratories (CDL), Kasauli last month.

Russian Covid-19 vaccine Sputnik V. Photo courtesy of The Russian Direct Investment Fund.

Full-scale production of the Sputnik V Covid vaccine began at Panacea Biotec’s facilities this summer.

The batch of the second component will be distributed in India through Dr. Reddy’s Laboratories, a partner of RDIF and Panacea Biotec.

Sputnik V has been authorized in 70 countries so far with a total population of more than four billion people.

Dr. Rajesh Jain — Managing Director of Panacea Biotec said: “Panacea Biotec is pleased to have successfully produced and dispatched the first batch of Component II (Ad5) of Sputnik V vaccine. More batches are currently under production at our manufacturing facility in Himachal Pradesh.”